ADC linkers, also known as antibody-drug conjugate linkers, play a crucial role in the development of antibody-drug conjugates (ADCs), a class of targeted cancer therapies. ADCs are designed to deliver potent cytotoxic drugs directly to cancer cells while sparing healthy tissues, potentially enhancing efficacy and reducing side effects compared to conventional chemotherapy. The linkers in ADCs serve as the intermediate component that connects the cytotoxic drug to the monoclonal antibody (mAb), facilitating targeted delivery of the drug to cancer cells.
Source https://adc.bocsci.com/products/adcs-linker-3239.html ↗